Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yiqi Gubiao Pill for Tuberculosis-related Obstructive Pulmonary Disease
NCT06676800Phase 1Not yet recruiting
- Sponsor
- Fourth Affiliated Hospital of Xinjiang Medical University
- Start
- Nov 2024
- Primary completion
- Feb 2025
- Modality
- TM (Traditional Medicine)
01
Overview
Phase 1, randomised, double-blind trial in Obstructive pulmonary disease (OPD) comparing Yiqi Gubiao pill Group with Placebo Group (2 arms). Primary endpoints: Forced Vital Capacity at 4 weeks, Percentage of FVC predicted at 4 weeks and 5 more. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
yiqi gubiao pill
03
Conditions
Obstructive pulmonary disease (OPD)
Beyond the preview
Go deeper on NCT06676800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06676800.